Evrysdi (risdiplam)

Two years risdiplam: New data from SUNFISH, JEWELFISH in infants, children, adults with spinal muscular atrophy (SMA)

Roche announces new 2-year risdiplam data to SUNFISH Part 1 showed risdiplam significantly improved motor function after 24 months of treatment in people aged 2-25 years with Types 2 or 3 SMA JEWELFISH study preliminary 12 month data in previously treated patients showed rapid and sustained increases in SMN protein levels Safety in SUNFISH and […]